Financing ·
Moleculin Biotech, Inc. completed a public offering of common stock and warrants on August 3, 2026, raising…
MBRXMoleculin Biotech, Inc.
Moleculin Biotech, Inc. completed a public offering of common stock and warrants on August 3, 2026, raising approximately $9.3 million in gross proceeds. The company issued 12,376,667 shares (or pre-funded warrants) alongside Series I Common Stock Purchase Warrants for up to 37,130,001 additional shares at a combined price of $0.75 per unit. Roth Capital Partners served as placement agent with a 6.5% fee, while Maxim Group acted as financial advisor for a 1.0% fee. Proceeds will fund clinical development of Annamycin and working capital needs. The company agreed to a 45-day lock-up on new issuances and an 180-day restriction on variable rate transactions. Moleculin Biotech operates in the biotechnology industry, focusing on drug discovery and development.